Fundz
New|Fundz now works inside Claude2 min

AI made execution free. Knowing first is the whole game now.

The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

Tolemy Bio secures €1.4M in pre-seed funding to enhance its AI-driven cell biology research technology, led by Norrsken Evolve.

PRIVATEMay 12, 2026•4 months ago

Amount Raised

€1.4 Million

Round Type

Pre-Seed

Cambridge

Investors

A New UK Based Stealth FundMasiaJme VenturesBig Sur VenturesNorrsken Evolve

Description

Cambridge-based Tolemy Bio has raised €1.4 million in pre-seed funding to advance its AI-enabled technology for cell biology research. The funding will be used to expand data generation and machine learning capabilities, as well as support early customer deployments. The round was led by Norrsken Evolve with participation from multiple investors. Tolemy Bio aims to optimize the fragmented workflows in biopharma and cell biology using its platform, Orbit.

Company Information

Company

Tolemy Bio

Location

Cambridge, England, United Kingdom

About

Tolemy Bio is a biotech startup that focuses on AI-enabled technology for cell biology research and biopharma development. The company is developing Orbit, a system designed to help researchers better understand and optimize living cells used in modern therapies. Tolemy Bio aims to streamline experimental workflows, which are currently fragmented and manual, to enhance the application of AI tools in drug development. The company's ultimate goal is to create a virtual-cell platform that facilitates more precise and data-driven experimentation in biopharma.

Fundz sees it the moment Tolemy Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsAlex W., Co-Founder hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Tolemy Bio's next move

See what Strategic adds

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tolemy Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.